http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105121417-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-593 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-40 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-593 |
| filingDate | 2014-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105121417-B |
| titleOfInvention | It is substituted the crystal type of thiazolylacetate triethylamine salt |
| abstract | The present invention relates to the crystal type of (2Z) 2 (base of 2 amino, 5 diuril azoles 4) 2 (3 N tertbutyloxycarbonylamino propoxyl group imino group) acetic acid (I) triethylamine salt.The invention further relates to the method and intermediate for preparing the crystal type.The crystal type can be used as preparing the intermediate of cross-linked glycopeptide cephalosporin antibiotics. |
| priorityDate | 2013-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.